PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis

This publication has 50 references indexed in Scilit:

• Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
  The Lancet, 2016
• Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma
  European Journal of Cancer, 2016
• The Role of PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis
  Immunotherapy, 2016
• A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry
  Journal of Thoracic Oncology, 2016
• Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
  JAMA Oncology, 2016
• Combination cancer immunotherapies tailored to the tumour microenvironment
  Nature Reviews Clinical Oncology, 2015
• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
  The Lancet Oncology, 2015
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
  Annals of Oncology, 2014
• Epidemiology of Brain Metastases
  Current Oncology Reports, 2011
• Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
  Cell, 2011